Rodriguez-Enriquez Sara

From Bioblast
(Redirected from Rodriguez-Enriquez S)


MiPsociety
News and Events        
BEC 2020.1 Mitochondrial physiology
       
MitoEAGLE
        Working Groups         Short-Term Scientific Missions         Management Committee         Members        
MitoGlobal
   


EU-logo.jpg

COST Action CA15203 (2016-2021): MitoEAGLE
Evolution-Age-Gender-Lifestyle-Environment: mitochondrial fitness mapping


Rodriguez-Enriquez Sara


MitoPedia topics: EAGLE 

COST: Member COST WG1: WG1


Name Rodriguez-Enriquez Sara, Dr., Investigador en Ciencias Medicas D

ORCID ID

Institution Department of Biochemistry,

National Institute of Cardiology, MX

Address Juan Badiano No. 1

Col. Seccion 16, 14080

City Tlalpan
State/Province
Country Mexico
Email [email protected]
Weblink
O2k-Network Lab MX Mexiko City Moreno-Sanchez R


Labels:



Publications

 PublishedReference
Robledo-Cadena 2024 PLoS One2024Robledo-Cadena DX, Pacheco-Velázquez SC, Vargas-Navarro JL, Padilla-Flores JA, López-Marure R, Pérez-Torres I, Kaambre T, Moreno-Sánchez R, Rodríguez-Enríquez S (2024) Synergistic celecoxib and dimethyl-celecoxib combinations block cervix cancer growth through multiple mechanisms. PLoS One 19:e0308233. https://doi.org/10.1371/journal.pone.0308233
Moreno-Sanchez 2022 MitoFit2022Moreno-Sánchez R, Robledo-Cadena DX, Pacheco-Velázquez SC, Rodríguez-Enríquez S (2022) Estimation of energy pathway fluxes in cancer cells- beyond the Warburg effect. https://doi.org/10.26124/mitofit:2022-0024
BEC 2020.1 doi10.26124bec2020-0001.v12020Gnaiger E et al ― MitoEAGLE Task Group (2020) Mitochondrial physiology. Bioenerg Commun 2020.1. https://doi.org/10.26124/bec:2020-0001.v1
Robledo-Cadena 2020 Pharmaceuticals (Basel)2020Robledo-Cadena DX, Gallardo-Pérez JC, Dávila-Borja V, Pacheco-Velázquez SC, Belmont-Díaz JA, Ralph SJ, Blanco-Carpintero BA, Moreno-Sánchez R, Rodríguez-Enríquez S (2020) Non-steroidal anti-inflammatory drugs increase cisplatin, paclitaxel, and doxorubicin efficacy against human cervix cancer cells. Pharmaceuticals (Basel) 13:463.
Rodriguez-Enriquez 2019 Toxicol Appl Pharmacol2019Rodríguez-Enríquez S, Pacheco-Velázquez SC, Marín-Hernández Á, Gallardo-Pérez JC, Robledo-Cadena DX, Hernández-Reséndiz I, García-García JD, Belmont-Díaz J, López-Marure R, Hernández-Esquivel L, Sánchez-Thomas R, Moreno-Sánchez R (2019) Resveratrol inhibits cancer cell proliferation by impairing oxidative phosphorylation and inducing oxidative stress. Toxicol Appl Pharmacol 370:65-77.
Pacheco-Velazquez 2018 Mol Pharm2018Pacheco-Velázquez SC, Robledo-Cadena DX, Hernández-Reséndiz I, Gallardo-Pérez JC, Moreno-Sánchez R, Rodríguez-Enríquez S (2018) Energy metabolism drugs block triple negative breast metastatic cancer cell phenotype. Mol Pharm 15:2151-64.
Hernandez-Resendiz 2018 J Cell Physiol2018Hernández-Reséndiz I, Gallardo-Pérez JC, López-Macay A, Robledo-Cadena DX, García-Villa E, Gariglio P, Saavedra E, Moreno-Sánchez R, Rodríguez-Enríquez S (2018) Mutant p53R248Q downregulates oxidative phosphorylation and upregulates glycolysis under normoxia and hypoxia in human cervix cancer cells. J Cell Physiol 234:5524-36.
Corona de la Pena 2017 PLoS One2017Corona de la Peña N, Gutiérrez-Aguilar M, Hernández-Reséndiz I, Marín-Hernández Á, Rodríguez-Enríquez S (2017) Glycoprotein Ib activation by thrombin stimulates the energy metabolism in human platelets. https://doi.org/10.1371/journal.pone.0182374
Moreno-Sanchez 2013 FEBS J2013Moreno-Sánchez R, Hernández-Esquivel L, Rivero-Segura NA, Marín-Hernández A, Neuzil J, Ralph SJ, Rodríguez-Enríquez S (2013) Reactive oxygen species are generated by the respiratory Complex II - evidence for lack of contribution of the reverse electron flow in Complex I. FEBS J 280:927-38.

Abstracts

 PublishedReference
Moreno-Sanchez 2022 Abstract Bioblast20226.2. «10+5»
Profile-icon-9.png
Moreno-Sanchez Rafael, Robledo-Cadena DX, Pacheco-Velázquez SC, Rodríguez-Enríquez S (2022) Estimation of energy pathway fluxes in cancer cells- beyond the Warburg effect. Bioblast 2022: BEC Inaugural Conference. In: https://doi.org/10.26124/bec:2022-0001
Cookies help us deliver our services. By using our services, you agree to our use of cookies.